Patricia Ntali
Psychiatric/Mental Health · Washington, DCNPI 1639731276
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 39 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by Alkermes, Inc. at 41.2% of the total. 2025 is the largest year on record at $373, more than ten times the $16 reported in 2021.
Across 39 payments — averaging $20.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$331
- Teva Pharmaceuticals USA, Inc.$154
- Otsuka America Pharmaceutical, Inc.$65
- Johnson & Johnson$61
- Neurocrine Biosciences, Inc.$54
- Lundbeck LLC$30
- plus $110 from 5 others
What the payments were for
- Food & beverage$804100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 18 | $331 |
| Teva Pharmaceuticals USA, Inc. | 7 | $154 |
| Otsuka America Pharmaceutical, Inc. | 3 | $65 |
| Johnson & Johnson | 2 | $61 |
| Neurocrine Biosciences, Inc. | 2 | $54 |
| Lundbeck LLC | 1 | $30 |
| Indivior Inc. | 2 | $30 |
| E.r. Squibb & Sons, L.L.C. | 1 | $25 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $20 |
| Orexo US, Inc. | 1 | $18 |
| Avanir Pharmaceuticals, Inc. | 1 | $17 |
How this compares
$804 in reported general payments places this provider in the 70th percentile of 137 psychiatric/mental health providers in District of Columbia.
See all psychiatric/mental health providers in District of Columbia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 146 | $447,317 |
| IngrezzaValbenazine Tosylate | 29 | $250,608 |
| AustedoDeutetrabenazine | 26 | $153,007 |
| Abilify MaintenaAripiprazole | 44 | $125,853 |
| AristadaAripiprazole Lauroxil | 22 | $68,285 |
| VraylarCariprazine Hcl | 37 | $54,212 |
| Aripiprazole | 115 | $5,757 |
| Paliperidone ErPaliperidone | 18 | $4,637 |
| Quetiapine Fumarate | 164 | $4,630 |
| Olanzapine | 124 | $3,885 |
| Haloperidol | 55 | $3,785 |
| Trazodone Hcl | 102 | $2,684 |
| Divalproex Sodium | 62 | $2,459 |
| Sertraline Hcl | 93 | $2,231 |
| Benztropine Mesylate | 113 | $2,155 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $61 | $447,317146 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $54 | $250,60829 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $154 | $153,00726 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $65 | $125,85344 claims |
| Alkermes, Inc.Aristada | $331 | $68,28522 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 137 psychiatric/mental health providers in District of Columbia.
Other psychiatric/mental health in Washington
- Erin WalczykowskiWashington$349K
- Caroline BonuWashington$16K
- Miriam EzenwakaWashington$6K
- Orin GreeneWashington$4K
- Hope AchoronyeWashington$4K
- Samantha HyltonWashington$4K
- Nkechi OnwucheWashington$4K
- Emmanuel Kamdem SangoWashington$4K
- Arithia HardenWashington$4K
- Zion DestaWashington$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.